A Phase 1 Study to Assess Mass Balance, Pharmacokinetics, and Metabolism of Orally Administered [14 C]-TAK-659 in Patients With Advanced Solid Tumor and/or Lymphoma Malignancies

Trial Profile

A Phase 1 Study to Assess Mass Balance, Pharmacokinetics, and Metabolism of Orally Administered [14 C]-TAK-659 in Patients With Advanced Solid Tumor and/or Lymphoma Malignancies

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 04 Apr 2018

At a glance

  • Drugs TAK 659 (Primary) ; TAK 659 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 26 Mar 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 26 Jan 2018 Planned End Date changed from 11 Jun 2019 to 1 May 2019.
    • 26 Jan 2018 Planned primary completion date changed from 29 Dec 2017 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top